Alexandre de Araújo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alexandre de Araújo has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Caroline Tortato
Hospital de Clínicas de Porto Alegre
3 shared publications - Mário Reis Álvares-Da-Silva
Graduate Program in Gastroenterology and Hepatology, Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil
3 shared publications - Paola Hoff Alves
Hospital de Clínicas de Porto Alegre
3 shared publications - Vittoria Sampaio
Hospital de Clínicas de Porto Alegre
3 shared publications - Cristina Coelho Borges Cheinquer
Faculdade de Medicina, Universidade do Vale do Rio dos Sinos (Unisinos), São Leopoldo, RS, Brasil
2 shared publications - Fernando Herz Wolff
Porto Alegre, RS, Brasil. Hospital Moinhos de Vento Unidade de Endoscopia Porto Alegre RS Brasil
2 shared publications
Latest Publications
- Open Access
- 1 January 2025
- Published by FapUNIFESP (SciELO) in ABCD. Arquivos Brasileiros de Cirurgia Digestiva (São Paulo)
- Vol. 38, e1893
Female donor gender is associated with a decrease in liver transplant survival of male recipients independent of donor and recipient anthropometrics
Background: Data on the influence of donor gender on post-liver transplant outcomes is scarce and is lacking. Aims: The aim of this study was to evaluate the prognostic factors of mortality in patients undergoing liver transplantation (LT) with a thorough evaluation of the influence of the donor variables. Methods: All patients undergoing LT at a single center from December 2011 to December 2018 were included. The main outcome measure of the study was overall patient survival. The mortality predictors were evaluated using Cox regression. Results: The study analyzed 202 patients, 118 (58.1%) being males, and the average age was 54.19±11.66 years. Post-LT survival for the entire cohort of 202 patients as assessed by the KaplanMeier method at 1, 3, 5, and 7 years was 81.6, 73.1, 67.6, and 63%, respectively. The only predictor of increased overall mortality was female donor gender [HR 1.918, 95%CI 1.150–3.201, p=0.013]. Weight and height differences between donor and recipient were not related to mortality (p=0.545 for weight and p=0.964 height). Conclusions: Female donor gender was associated with an increase in overall post-LT mortality, especially for male recipients, regardless of anthropometric parameters. For male patients receiving livers from female donors, infection was the most common cause of mortality, occurring in the first year following LT.
- 1 January 2025
- Published by FapUNIFESP (SciELO) in ABCD. Arquivos Brasileiros de Cirurgia Digestiva (São Paulo)
- Vol. 38, e1893
Open AccessFemale donor gender is associated with a decrease in liver transplant survival of male recipients independent of donor and recipient anthropometrics
Background: Data on the influence of donor gender on post-liver transplant outcomes is scarce and is lacking. Aims: The aim of this study was to evaluate the prognostic factors of mortality in patients undergoing liver transplantation (LT) with a thorough evaluation of the influence of the donor variables. Methods: All patients undergoing LT at a single center from December 2011 to December 2018 were included. The main outcome measure of the study was overall patient survival. The mortality predictors were evaluated using Cox regression. Results: The study analyzed 202 patients, 118 (58.1%) being males, and the average age was 54.19±11.66 years. Post-LT survival for the entire cohort of 202 patients as assessed by the KaplanMeier method at 1, 3, 5, and 7 years was 81.6, 73.1, 67.6, and 63%, respectively. The only predictor of increased overall mortality was female donor gender [HR 1.918, 95%CI 1.150–3.201, p=0.013]. Weight and height differences between donor and recipient were not related to mortality (p=0.545 for weight and p=0.964 height). Conclusions: Female donor gender was associated with an increase in overall post-LT mortality, especially for male recipients, regardless of anthropometric parameters. For male patients receiving livers from female donors, infection was the most common cause of mortality, occurring in the first year following LT.
- Open Access
- 7 May 2024
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 68, e220480
Impact of sustained virologic response on glucose parameters among patients with chronic hepatitis C treated with direct-acting antivirals
Objective: The aim of this study was to evaluate the glycated hemoglobin (HbA1c) levels before and after sustained virologic response (SVR) and investigate the baseline characteristics associated with improved glycemic control in patients with chronic hepatitis C (CHC) achieving SVR after direct-acting antivirals (DAA) therapy. Materials and methods: Consecutive adult patients with CHC who achieved SVR after DAA treatment between January 2016 and December 2017 at Hospital de Clínicas de Porto Alegre (RS, Brazil) were prospectively included. Levels of [...] ABSTRACT Objective: The aim of this study was to evaluate the glycated hemoglobin (HbA1c) levels before and after sustained virologic response (SVR) and investigate the baseline characteristics associated with improved glycemic control in patients with chronic hepatitis C (CHC) achieving SVR after direct-acting antivirals (DAA) therapy. Materials and methods: Consecutive adult patients with CHC who achieved SVR after DAA treatment between January 2016 and December 2017 at Hospital de Clínicas de Porto Alegre (RS, Brazil) were prospectively included. Levels of
- 7 May 2024
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 68, e220480
Open AccessImpact of sustained virologic response on glucose parameters among patients with chronic hepatitis C treated with direct-acting antivirals
Objective: The aim of this study was to evaluate the glycated hemoglobin (HbA1c) levels before and after sustained virologic response (SVR) and investigate the baseline characteristics associated with improved glycemic control in patients with chronic hepatitis C (CHC) achieving SVR after direct-acting antivirals (DAA) therapy. Materials and methods: Consecutive adult patients with CHC who achieved SVR after DAA treatment between January 2016 and December 2017 at Hospital de Clínicas de Porto Alegre (RS, Brazil) were prospectively included. Levels of [...] ABSTRACT Objective: The aim of this study was to evaluate the glycated hemoglobin (HbA1c) levels before and after sustained virologic response (SVR) and investigate the baseline characteristics associated with improved glycemic control in patients with chronic hepatitis C (CHC) achieving SVR after direct-acting antivirals (DAA) therapy. Materials and methods: Consecutive adult patients with CHC who achieved SVR after DAA treatment between January 2016 and December 2017 at Hospital de Clínicas de Porto Alegre (RS, Brazil) were prospectively included. Levels of
- Open Access
- 30 November 2022
- Published by Associacao Brasileira de Transplantes de Orgaos in Brazilian Journal of Transplantation
- Vol. 25 (4)
Tempo entre Início do Uso de Tacrolimo e Nível Sanguíneo Alvo em Pacientes Pós-Transplante Hepático Adulto
Introdução: O tacrolimo é um dos imunossupressores mais utilizados em pacientes após transplante hepático e com frequência se observa uma grande variação no seu nível sanguíneo (NS). Avaliar o tempo médio para se alcançar o NS alvo de tacrolimo pós-transplante hepático é fundamental, pois níveis muito baixos aumentam as chances de rejeição ao enxerto, e níveis muito altos estão associados a toxicidade. Método: Estudo de coorte observacional, retrospectivo, conduzido no Hospital de Clínicas de Porto Alegre. Foram incluídos pacientes transplantados hepáticos entre dezembro de 2012 e dezembro de 2017 em uso de tacrolimo via oral. Foram considerados com NS alvo pacientes que atingiram NS entre 6–8 ng/mL durante o primeiro mês pós-transplante. Resultados: 78% (67/87) dos pacientes atingiram o NS alvo em até 10 dias após o transplante hepático. Pacientes que apresentaram rejeição ao longo de 1 ano após o transplante demoraram em torno de 9 dias para atingir o NS alvo durante a internação-índice versus 7 dias em pacientes que não apresentaram rejeição. Conclusão: Nosso trabalho, ao considerar alvo terapêutico valores entre 6–8 ng/mL em pacientes pós-transplante imediato de fígado, demonstrou que essa população teve um tempo médio que parece determinar bom prognóstico, uma vez que, em menos de 2 semanas, 78% dos pacientes atingiram NS alvo perto do preconizado.
- 30 November 2022
- Published by Associacao Brasileira de Transplantes de Orgaos in Brazilian Journal of Transplantation
- Vol. 25 (4)
Open AccessTempo entre Início do Uso de Tacrolimo e Nível Sanguíneo Alvo em Pacientes Pós-Transplante Hepático Adulto
Introdução: O tacrolimo é um dos imunossupressores mais utilizados em pacientes após transplante hepático e com frequência se observa uma grande variação no seu nível sanguíneo (NS). Avaliar o tempo médio para se alcançar o NS alvo de tacrolimo pós-transplante hepático é fundamental, pois níveis muito baixos aumentam as chances de rejeição ao enxerto, e níveis muito altos estão associados a toxicidade. Método: Estudo de coorte observacional, retrospectivo, conduzido no Hospital de Clínicas de Porto Alegre. Foram incluídos pacientes transplantados hepáticos entre dezembro de 2012 e dezembro de 2017 em uso de tacrolimo via oral. Foram considerados com NS alvo pacientes que atingiram NS entre 6–8 ng/mL durante o primeiro mês pós-transplante. Resultados: 78% (67/87) dos pacientes atingiram o NS alvo em até 10 dias após o transplante hepático. Pacientes que apresentaram rejeição ao longo de 1 ano após o transplante demoraram em torno de 9 dias para atingir o NS alvo durante a internação-índice versus 7 dias em pacientes que não apresentaram rejeição. Conclusão: Nosso trabalho, ao considerar alvo terapêutico valores entre 6–8 ng/mL em pacientes pós-transplante imediato de fígado, demonstrou que essa população teve um tempo médio que parece determinar bom prognóstico, uma vez que, em menos de 2 semanas, 78% dos pacientes atingiram NS alvo perto do preconizado.
- Open Access
- 30 November 2022
- Published by Associacao Brasileira de Transplantes de Orgaos in Brazilian Journal of Transplantation
- Vol. 25 (4)
Time Between Start of Tacrolimus Use and Target Serum Level in Patients After Adult Liver Transplantation
Introduction: Tacrolimus is one of the most used immunosuppressants in patients after liver transplantation and there is often a wide variation in its serum level. Assessing the mean time to reach the target serum level of tacrolimus after liver transplantation is critical, as very low levels increase with chances of graft rejection and very high levels are associated with toxicity. Methodology:Observational, retrospective cohort study conducted at Hospital de Clínicas de Porto Alegre. Liver transplant patients between December 2012 and December 2017 using oral tacrolimus were included. Patients who reached a serum level between 6–8 ng/mL during month 1 post-transplant were considered as target serum levels. Results: 78% (67/87) of patients reached the target serum level within 10 days after liver transplantation. Patients who experienced rejection over 1 year after transplantation took around 9 days to reach the target serum level during the index hospital stay. Patients who did not present rejection reached target serum level within 7 days after starting the immunosuppressant. Conclusion: Our work, considering therapeutic target values between 6–8 ng/mL in patients after immediate liver transplantation, demonstrated that this population performed a mean time that seems to determine a good prognosis, since in less than 2 weeks 78% of patients reached target serum level close to what was recommended.
- 30 November 2022
- Published by Associacao Brasileira de Transplantes de Orgaos in Brazilian Journal of Transplantation
- Vol. 25 (4)
Open AccessTime Between Start of Tacrolimus Use and Target Serum Level in Patients After Adult Liver Transplantation
Introduction: Tacrolimus is one of the most used immunosuppressants in patients after liver transplantation and there is often a wide variation in its serum level. Assessing the mean time to reach the target serum level of tacrolimus after liver transplantation is critical, as very low levels increase with chances of graft rejection and very high levels are associated with toxicity. Methodology:Observational, retrospective cohort study conducted at Hospital de Clínicas de Porto Alegre. Liver transplant patients between December 2012 and December 2017 using oral tacrolimus were included. Patients who reached a serum level between 6–8 ng/mL during month 1 post-transplant were considered as target serum levels. Results: 78% (67/87) of patients reached the target serum level within 10 days after liver transplantation. Patients who experienced rejection over 1 year after transplantation took around 9 days to reach the target serum level during the index hospital stay. Patients who did not present rejection reached target serum level within 7 days after starting the immunosuppressant. Conclusion: Our work, considering therapeutic target values between 6–8 ng/mL in patients after immediate liver transplantation, demonstrated that this population performed a mean time that seems to determine a good prognosis, since in less than 2 weeks 78% of patients reached target serum level close to what was recommended.
- Open Access
- 30 November 2022
- Published by Associacao Brasileira de Transplantes de Orgaos in Brazilian Journal of Transplantation
- Vol. 25 (4)
Tiempo entre el Uso de Tacrolimo y el Nivel Sérico Objetivo en Pacientes Después de un Trasplante Hepático en Adultos
Introducción: El tacrolimo es uno de los inmunosupresores más utilizados en pacientes postrasplante hepático y suele existir una amplia variación en su nivel sérico. Es fundamental evaluar el tiempo medio para alcanzar el nivel sérico (NS) objetivo de tacrolimo después del trasplante de hígado, ya que los niveles muy bajos aumentan las posibilidades de rechazo del injerto y los niveles muy altos se asocian con toxicidad. Metodología: Estudio observacional de cohorte retrospectivo realizado en el Hospital de Clínicas de Porto Alegre. Se incluyeron pacientes trasplantados de hígado entre diciembre de 2012 y diciembre de 2017 en uso de tacrolimo oral. Los pacientes que alcanzaron un nivel sérico entre 6 y 8 ng/mL durante el mes 1 posterior al trasplante se consideraron un nivel sérico objetivo. Resultados: el 78% (67/87) de los pacientes alcanzaron el NS objetivo dentro de los 10 días posteriores al trasplante hepático. Los pacientes que experimentaron rechazo más de 1 año después del trasplante tardaron alrededor de 9 días en alcanzar el SL objetivo durante la hospitalización-índice frente a los 7 días de los pacientes que no experimentaron rechazo. Conclusión:Nuestro estudio, al considerar valores objetivo terapéuticos entre 6-8 ng/mL en pacientes postrasplante hepático inmediato, mostró que esta población realizó un tiempo promedio que parece determinar un buen pronóstico ya que en menos de 2 semanas el 78% de los pacientes alcanzaron el objetivo de NS cercano al recomendado.
- 30 November 2022
- Published by Associacao Brasileira de Transplantes de Orgaos in Brazilian Journal of Transplantation
- Vol. 25 (4)
Open AccessTiempo entre el Uso de Tacrolimo y el Nivel Sérico Objetivo en Pacientes Después de un Trasplante Hepático en Adultos
Introducción: El tacrolimo es uno de los inmunosupresores más utilizados en pacientes postrasplante hepático y suele existir una amplia variación en su nivel sérico. Es fundamental evaluar el tiempo medio para alcanzar el nivel sérico (NS) objetivo de tacrolimo después del trasplante de hígado, ya que los niveles muy bajos aumentan las posibilidades de rechazo del injerto y los niveles muy altos se asocian con toxicidad. Metodología: Estudio observacional de cohorte retrospectivo realizado en el Hospital de Clínicas de Porto Alegre. Se incluyeron pacientes trasplantados de hígado entre diciembre de 2012 y diciembre de 2017 en uso de tacrolimo oral. Los pacientes que alcanzaron un nivel sérico entre 6 y 8 ng/mL durante el mes 1 posterior al trasplante se consideraron un nivel sérico objetivo. Resultados: el 78% (67/87) de los pacientes alcanzaron el NS objetivo dentro de los 10 días posteriores al trasplante hepático. Los pacientes que experimentaron rechazo más de 1 año después del trasplante tardaron alrededor de 9 días en alcanzar el SL objetivo durante la hospitalización-índice frente a los 7 días de los pacientes que no experimentaron rechazo. Conclusión:Nuestro estudio, al considerar valores objetivo terapéuticos entre 6-8 ng/mL en pacientes postrasplante hepático inmediato, mostró que esta población realizó un tiempo promedio que parece determinar un buen pronóstico ya que en menos de 2 semanas el 78% de los pacientes alcanzaron el objetivo de NS cercano al recomendado.
- Open Access
- 1 September 2021
- Published by Elsevier in Annals of Hepatology
- Vol. 24, 100369
P-3 IMPACT OF THE SUSTAINED VIROLOGICAL RESPONSE ON THE GLUCOSE METABOLISM IN PATIENTS WITH HEPATITIS C
- 1 September 2021
- Published by Elsevier in Annals of Hepatology
- Vol. 24, 100369
Open AccessP-3 IMPACT OF THE SUSTAINED VIROLOGICAL RESPONSE ON THE GLUCOSE METABOLISM IN PATIENTS WITH HEPATITIS C